エピソード

  • Colombia's UDI Mandate: Pure Global on a New MedTech Compliance Trap

    Colombia's UDI Mandate: Pure Global on a New MedTech Compliance Trap
    2026/05/07
    This episode of LATAM MedTech Insights dives into a sudden and critical regulatory update from Colombia's INVIMA. Last week's clarification on Unique Device Identification (UDI) for Class IIa devices has created an immediate compliance challenge for manufacturers, requiring a new level of data management and specific submission protocols that have caught many off guard. We break down what the new guidance entails, the technical hurdles it presents, and the broader implications for MedTech companies operating in, or planning to enter, the Colombian market. We explore why this move is more than a simple labeling change and represents a significant step-up in local enforcement of global standards. A leading US-based orthopedic company, which packages multiple devices into single surgical kits, is now facing potential import blockades. Their global UDI strategy did not account for INVIMA's new demand for individual Device Identifier linking for every single Class IIa component within a kit. This case study reveals the hidden complexities and the urgent need to overhaul their data management systems to meet Colombia’s unique requirements. --- **Key Takeaways:** 1. What are the exact technical data points INVIMA now requires for UDI-DI registration linking? 2. Is your current local representative in Colombia equipped to handle these new digital submission requirements? 3. How does this UDI update affect devices that are already on the market versus new registrations? 4. What are the specific Spanish-language documentation requirements that could trip up your submission? 5. If your product is part of a kit, what is the new compliance burden you urgently need to address? 6. Could this sudden enforcement approach from INVIMA be a sign of future regulatory trends in Peru or Chile? 7. What is the real financial risk of having your products detained at Colombian customs due to non-compliance? --- At Pure Global, we specialize in navigating these complex regulatory landscapes. We offer end-to-end solutions for MedTech and IVD companies, combining local expertise with advanced AI and data tools to streamline global market access. Whether it's managing UDI compliance in Colombia or developing a regulatory strategy for over 30 markets worldwide, we act as your local representative to ensure you maintain market presence. Don't let regulatory surprises disrupt your business. Contact Pure Global at info@pureglobal.com or visit us at https://pureglobal.com/.
    続きを読む 一部表示
    2 分
  • Pure Global: Chile's MedTech Surprise - Cracking Decree 25's Hidden Regulatory Hurdles.

    Pure Global: Chile's MedTech Surprise - Cracking Decree 25's Hidden Regulatory Hurdles.
    2026/05/06
    This week on LATAM MedTech Insights, we dissect the impactful new regulations quietly introduced in Chile. Exempt Decree No. 25 has significantly expanded the oversight of the national health authority, the ISP, reshaping the compliance landscape for many medical device manufacturers who previously had an easier path to market. We dive into the specifics of what this decree means for your product portfolio, the new registration and surveillance demands you need to be aware of, and the broader implications for the Latin American MedTech market. This is a critical update for anyone operating in or planning to enter Chile. A specific case involves a US-based diagnostics company that saw its projected launch timeline in Chile triple overnight. Their devices, once subject to a simple notification process, are now under the full scope of Decree 25, requiring a comprehensive regulatory submission they were completely unprepared for, jeopardizing their entire regional expansion plan. Key Takeaways: - What is Chile's Exempt Decree No. 25 and which devices does it suddenly affect? - How does this change impact time-to-market and costs for MedTech companies? - Is your current product portfolio compliant with the ISP's newly expanded oversight? - Why is this seemingly small decree a major signal for the entire LATAM region's regulatory future? - What are the three immediate steps you must take to de-risk your Chilean market strategy? - How can you leverage your existing technical documentation for the new requirements? - Could these stricter rules actually create a competitive advantage for well-prepared companies? Pure Global offers end-to-end regulatory consulting solutions for Medical Technology (MedTech) and In-Vitro Diagnostic (IVD) companies, combining local expertise with advanced AI and data tools to streamline global market access. Contact Pure Global at info@pureglobal.com or visit us at https://pureglobal.com/.
    続きを読む 一部表示
    2 分
  • Brazil's AI MedTech Firewall: Pure Global on Cracking ANVISA's Surprise Cybersecurity Mandate

    Brazil's AI MedTech Firewall: Pure Global on Cracking ANVISA's Surprise Cybersecurity Mandate
    2026/05/05
    Last week, Brazil's regulatory landscape for MedTech was redefined. ANVISA, the national health agency, unexpectedly rolled out a stringent new framework mandating advanced cybersecurity and data privacy compliance for all AI-driven medical devices. This sudden move disrupts market-entry plans and forces an immediate re-evaluation of regulatory strategies for companies targeting Latin America's largest market. This episode dives deep into the practical consequences of this new regulation. We break down the specific documentation now required, from threat modeling to LGPD compliance, and analyze why simply leveraging your existing FDA or CE Mark approval is no longer a viable path to market access in Brazil. **Key Questions Answered in This Episode:** * What are the specific cybersecurity protocols ANVISA now demands for AI-enabled devices? * How does this new regulation intersect with Brazil's data protection law, the LGPD? * Why is my existing international documentation suddenly insufficient for a Brazilian submission? * What is the single biggest risk for MedTech startups trying to navigate this new rule? * How can this regulatory hurdle be turned into a competitive advantage? * What immediate steps should your company take to de-risk your market entry plan for Brazil? * Are there any "hidden" requirements in the new resolution that could delay your launch? Don't let regulatory hurdles block your access to the vibrant LATAM market. Pure Global combines local expertise with AI-powered data tools to streamline your path to compliance and success. From market access strategy to local representation, we offer end-to-end solutions for MedTech and IVD innovators. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can accelerate your global expansion.
    続きを読む 一部表示
    2 分
  • Pure Global: Brazil's New SaMD Hurdle & The Hidden AI Challenge

    Pure Global: Brazil's New SaMD Hurdle & The Hidden AI Challenge
    2026/05/04
    This week, we dissect a game-changing regulatory update from Brazil's ANVISA that directly impacts AI-powered medical devices. Brazil has introduced a mandatory "Algorithm Change Protocol" for all Software as a Medical Device (SaMD), creating a new, complex layer of requirements that surpasses current FDA and EU standards. This change is already causing submission delays for unprepared companies. We explore what this new protocol entails, why ANVISA is taking this assertive step, and what it means for your LATAM market access strategy. This episode provides essential insights for any MedTech manufacturer looking to launch AI-driven technologies in Latin America's largest market. Don't let this unexpected hurdle derail your expansion plans. **Key Questions Answered:** * What is the new "Algorithm Change Protocol" that ANVISA now requires for all AI-based SaMD? * Why is your existing FDA or CE-marked technical file suddenly insufficient for Brazil? * How does this update specifically impact SaMD for diagnostic imaging versus therapeutic applications? * What are the immediate costs and timeline delays if this protocol is missing from your submission? * How can you proactively build this protocol into your Quality Management System? * Is this a sign of a broader regulatory trend across other LATAM countries? * What are the top three mistakes companies make when trying to meet these new AI documentation rules? At Pure Global, we specialize in navigating these complex and evolving regulatory landscapes. Our team of local experts, powered by advanced AI tools, provides end-to-end solutions to get your MedTech and IVD products to market efficiently. From developing a robust regulatory strategy and compiling technical dossiers to acting as your official in-country representative, we streamline your access to over 30 global markets, including Brazil. Don't let regulatory surprises slow you down. Contact us at info@pureglobal.com or visit https://pureglobal.com to learn more.
    続きを読む 一部表示
    2 分
  • Pure Global: Brazil's AI MedTech Shock—Navigating ANVISA's New Data Rules.

    Pure Global: Brazil's AI MedTech Shock—Navigating ANVISA's New Data Rules.
    2026/05/03
    This week, we dissect the immediate fallout from Brazil's surprise new regulation, ANVISA RDC 925/2026. This sudden rule change for AI-powered medical software has blindsided many international MedTech companies, creating significant new hurdles for entry into Latin America's largest market. We explore how the mandate for local Brazilian clinical data and stringent LGPD-aligned cybersecurity protocols is forcing companies to scrap their existing market access strategies. This isn't just another piece of red tape. it's a fundamental shift that could delay product launches by more than a year and add millions to the cost. **Featured Case:** Imagine a promising MedTech scale-up, armed with FDA clearance and a robust set of clinical data from the US. Their plan for a quick Brazilian launch is abruptly halted by the new ANVISA rule. Their "gold-standard" clinical data is now deemed insufficient, and their global cybersecurity framework is non-compliant. They now face a critical decision: invest in a costly, time-consuming local trial and data-system overhaul, or abandon the market entirely. **Key Questions Answered in This Episode:** * How does ANVISA's new rule redefine "sufficient" clinical data for AI medical devices? * What specific LGPD cybersecurity measures are now mandatory for your SaMD to be approved in Brazil? * Can you leverage your existing FDA or CE marking to fast-track any part of the new process? * What is the most common blind spot for foreign companies when interpreting these new requirements? * How can you turn this regulatory hurdle into a strategic advantage in the LATAM market? * Does this new resolution signal a wider protectionist trend across other Latin American markets? Navigating the complexities of global MedTech regulations is our expertise. Pure Global offers end-to-end regulatory consulting solutions, combining local expertise with advanced AI and data tools to streamline your market access. Don't let regulatory surprises derail your expansion. Contact us at info@pureglobal.com or visit us at https://pureglobal.com/ for a strategic consultation.
    続きを読む 一部表示
    2 分
  • Pure Global: Brazil's AI MedTech Maze - Cracking ANVISA's New Software Rules

    Pure Global: Brazil's AI MedTech Maze - Cracking ANVISA's New Software Rules
    2026/05/01
    Brazil's health regulatory agency, ANVISA, has just released a groundbreaking new framework for Software as a Medical Device (SaMD), creating significant new challenges for global MedTech innovators. This update introduces stricter requirements for clinical data and cybersecurity, tailored specifically to the Brazilian context. This policy shift is forcing international companies to rethink their market entry strategies, as regulatory dossiers approved in other major markets may no longer be adequate. Imagine your AI-powered diagnostic tool, which has already received CE marking, being rejected by ANVISA because its validation data doesn't reflect Brazil's diverse population and its data servers aren't localized. This is the new reality, where overlooking local nuances can lead to costly delays and missed opportunities. Key Takeaways: - What specific cybersecurity protocols are now mandatory under ANVISA's new SaMD resolution? - How can you gather clinical data that meets the new requirements for representing the Brazilian population? - Can your existing EU MDR or FDA documentation be leveraged, or do you need to start from scratch for Brazil? - What are the common pitfalls when appointing a Brazil Registration Holder for a complex SaMD product? - What are the new labeling requirements for AI-powered devices regarding transparency and performance? - How does Brazil's General Data Protection Law, the LGPD, intersect with these new ANVISA regulations? - Is it more strategic to partner with a local entity or establish a subsidiary to meet the new compliance demands? Struggling to keep up with these changes? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. Contact us for a strategic consultation at info@pureglobal.com or visit us at https://pureglobal.com.
    続きを読む 一部表示
    2 分
  • Pure Global: Brazil's AI Device Maze - Decoding ANVISA's Unseen SaMD Hurdles

    Pure Global: Brazil's AI Device Maze - Decoding ANVISA's Unseen SaMD Hurdles
    2026/04/30
    This week, we dive into a major regulatory shift in Latin America's largest market. Brazil's ANVISA has just rolled out a comprehensive and demanding new framework for Software as a Medical Device (SaMD), directly impacting AI-driven diagnostics and digital health platforms. We break down what these changes mean for market access. We explore the challenges through the case of a medical AI company. Their market entry plan for Brazil was solid, but the new regulations suddenly made their existing documentation obsolete. Now they face the critical risk of misclassifying their device, which could lead to costly delays and outright rejection by ANVISA. This episode is a must-listen for innovators looking to enter or expand in Brazil. Key Takeaways: - How does ANVISA's new risk classification for software differ from the FDA and EU MDR frameworks? - What are the most common documentation gaps that will lead to rejection under the new SaMD rules? - Are your current cybersecurity protocols sufficient to meet Brazil's stringent new requirements? - How can you leverage your existing clinical data for a successful Brazilian submission? - What specific post-market surveillance activities does ANVISA now expect from SaMD manufacturers? - Could this new regulation actually accelerate market entry for companies that are properly prepared? At Pure Global, we specialize in turning regulatory complexity into a competitive advantage. With our on-the-ground experts in Brazil and advanced AI-powered data tools, we provide end-to-end regulatory consulting to ensure your MedTech and IVD products achieve seamless market access. Don't let regulatory hurdles block your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can streamline your entry into over 30 global markets.
    続きを読む 一部表示
    2 分
  • Pure Global: Brazil's AI MedTech Surge - Unlocking ANVISA's New Fast-Track Secrets.

    Pure Global: Brazil's AI MedTech Surge - Unlocking ANVISA's New Fast-Track Secrets.
    2026/04/29
    In this episode, we dissect the groundbreaking new resolution from Brazil's ANVISA that creates a fast-track approval pathway for AI-powered Software as a Medical Device (SaMD). This regulatory shift is set to drastically reduce time-to-market, from years to mere months, for cutting-edge digital health technologies in Latin America's largest healthcare market. We explore the specific requirements, the immense opportunities for global MedTech innovators, and the new compliance challenges related to cybersecurity and post-market surveillance. This change signals a new era for MedTech in Brazil, creating a powerful incentive for companies to invest and expand their footprint in the region. Case in Point: Imagine your innovative AI diagnostic tool, already approved in the US, is blocked from the 215 million-person Brazilian market by a slow, outdated regulatory system. You've spent years in development, and now face a three-year waiting period filled with uncertainty and mounting costs, while patients are deprived of your technology. This was the reality for many, but last week's ANVISA announcement changes everything, presenting a golden opportunity, but also a complex new set of rules to master. Key Takeaways: * What specific changes did ANVISA just implement for AI-powered medical devices? * How does this new fast-track process actually work, and who is eligible to apply? * Are there hidden risks or compliance traps in the new Brazilian cybersecurity requirements? * Which international companies are best positioned to capitalize on this regulatory shift first? * Will Mexico's COFEPRIS or Argentina's ANMAT now follow Brazil's lead? * How can you leverage existing FDA or CE Mark dossiers for the new Brazilian pathway? * What are the new, stricter post-market surveillance demands for SaMD in Brazil? Pure Global offers end-to-end regulatory consulting solutions to help MedTech and IVD companies navigate these complexities. We combine local expertise with advanced AI and data tools to streamline your global market access, acting as your local representative and ensuring your technical dossiers meet ANVISA's new requirements. To accelerate your entry into the Brazilian market and beyond, contact us at info@pureglobal.com or visit https://pureglobal.com/.
    続きを読む 一部表示
    2 分